The first EU Joint Clinical Assessments (JCAs) are now providing real-world evidence of how the new EU HTA process is working in practice. As additional assessments are published and Member States begin integrating JCA outputs into national HTA and reimbursement processes, broader patterns and practical considerations are starting to emerge.
In this on-demand webinar, Remap’s HTA experts examine the emerging lessons from the first JCAs and what they mean for future submissions. The discussion explores evolving evidence expectations, early national implementation and the practical actions manufacturers can take to strengthen evidence planning, organisational readiness and future European market access strategies.
Access the Recording
What the session covers
- Emerging lessons from the first EU Joint Clinical Assessments, including recurring patterns, challenges and differences between assessments.
- What the early JCAs reveal about evidence expectations, including PICO strategy, direct and indirect comparative evidence, methodological scrutiny and requests for additional analyses.
- The practical implications for evidence planning, submission strategy, organisational readiness and future JCA submissions.
- How Member States are beginning to integrate JCA outputs into national HTA and reimbursement processes.
- The key uncertainties that remain as implementation evolves and the actions manufacturers can take now to strengthen future submission readiness.